Preventive Catheter Ablation for Ventricular Arrhythmias in Patients with End-Stage Heart Failure Referred for Heart Transplantation Evaluation: Rationale for and Design of the CASTLE-VT Trial
Authors:
Open Access
- 11 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 27 (4) , 690-696
Abstract
Aims: Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage heart faiLure rEferred for heart transplantation eValuaTion (CASTLE-VT) trial is to test the hypothesis that prophylactic catheter ablation of arrhythmogenic ventricular scar tissue will reduce mortality, need for LVAD implantation, and urgent HTx in patients with end-stage HF related to ischaemic cardiomyopathy (ICM). Methods: CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary endpoint is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study endpoints are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia/ventricular fibrillation episodes, left ventricular function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow-up period of 2 years. Conclusion: CASTLE-VT will determine whether prophylactic catheter ablation of arrhythmogenic ventricular scar tissue reduces mortality in patients with end-stage HF who are referred for HTx evaluation.Keywords
This publication has 22 references indexed in Scilit:
- Catheter Ablation in End-Stage Heart Failure with Atrial FibrillationNew England Journal of Medicine, 2023
- Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection FractionJAMA Cardiology, 2022
- Comparing Short-Term Outcome after Implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®ESC Heart Failure, 2020
- Facilitating heart transplantability in an end-stage heart failure patient with brain abscess and infected left ventricle assist device—A unique case reportInternational Journal of Surgery Case Reports, 2020
- Continuously Updated Estimation of Heart Transplant Waitlist MortalityJACC, 2018
- Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2018
- New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trialsAmerican Heart Journal, 2017
- 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant)JACC, 2017
- Utility of Patient-Reported Outcome Instruments in Heart FailureJACC: Heart Failure, 2016
- The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year updateThe Journal of Heart and Lung Transplantation, 2016